EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan iD

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Sameer Mir und 8 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda…. Hauptthemen laut MEDLINE: Mesothelin, Stomach Neoplasms, Colorectal Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program of the NIH, NCI NIH HHS, CCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with advanced gastric and colorectal cancers have limited treatment options. Since mesothelin is highly expressed in these tumour types, we evaluated the therapeutic benefits of anti‐mesothelin hYP218 CAR T cells alone, and in combination with anti‐PD1 antibody, pembrolizumab. GEPIA analysis was performed using human gastric ( n = 408) and colon cancer tumours ( n = 275) in TCGA database, to evaluate mRNA expression of mesothelin, compared to normal tissues. Mesothelin expression in gastric and colorectal cancer cell‐lines ( n = 5) was analysed using flow cytometry. In vitro efficacy by hYP218 CAR T cells was tested by cytotoxicity and cytokine release assays. In vivo anti‐tumour efficacy of hYP218 CAR T cells alone, and in combination with pembrolizumab, was evaluated in NSG mice bearing human gastric (HGC27) and colorectal (SW48) tumour xenografts. Additionally, hYP218 CAR‐T cell persistence, activation and exhaustion marker‐expression were studied. Mesothelin expression was significantly higher in gastric and colon cancer biopsies compared to normal tissues ( p < .005). Mesothelin expression in gastric and colon cancer cell lines ranged from 10 000 to 70 000 molecules per cell. hYP218 CAR T cells demonstrated strong cytotoxic activity at low effector to target ratio, ranging from 0.24 to 1.0. In NSG mouse‐models, hYP218 CAR T cells demonstrated anti‐tumour efficacy and persisted in the tumour microenvironment in a functional state at day 40 posttreatment with expression of activation markers CD39 and CD69, increased production of IFN‐γ and TNF‐α and ability to kill tumour cells in vitro when isolated from tumours. There was increased PD1 expression. In combination with pembrolizumab, hYP218 CAR T cells led to slower tumour growth in NSG mice bearing large but not small HGC27 tumours. Anti‐tumour efficacy of hYP218 CAR T cells is due to increased accumulation of activated CAR T cells in the tumour and combination with pembrolizumab resulted in improvement in anti‐tumour activity of large established tumours. Highlights Mesothelin expression is significantly higher in gastric and colorectal cancers than normal tissues. hYP218 CAR T cells demonstrate strong anti‐tumour activity against mesothelin‐positive gastric and colorectal carcinomas. Activated hYP218 CAR T cells persist in the tumour microenvironment and retain their cytotoxic activity. Addition of pembrolizumab in larger tumours enhance CAR T cell efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesothelinStomach NeoplasmsColorectal NeoplasmsReceptors, Chimeric AntigenHumansMiceAnimalsCell Line, TumorImmunotherapy, AdoptiveGPI-Linked Proteins

Stichwörter der Autor:innen

CAR T cellanti‐PD1colorectal cancergastric cancermesothelinpembrolizumabxenograft cancer model

Substanzen

MesothelinReceptors, Chimeric AntigenGPI-Linked Proteins

Autor:innen und Institutionen

  • Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Cancer Data Science Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA.

ORCID-Profile: Raffit Hassan

Förderung

  • Intramural Research Program of the NIH
  • NCI NIH HHS
  • CCR NIH HHS
  • National Cancer Institute
  • Center for Cancer Research

Zitieren

APA

Mir, S., Venugopalan, A., Zhang, J., Nair, N. U., Sengupta, M., Khanal, M., Stathopoulou, C., Jiang, Q., & Hassan, R. (2024). Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70057

Vancouver

Mir S, Venugopalan A, Zhang J, Nair NU, Sengupta M, Khanal M, et al. Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.70057

BibTeX
@article{Mir2024,
  author = {Mir, Sameer and Venugopalan, Abhilash and Zhang, Jingli and Nair, Nishanth Ulhas and Sengupta, Manjistha and Khanal, Manakamana and Stathopoulou, Chaido and Jiang, Qun and Hassan, Raffit},
  title = {Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.70057}
}
Kostenlos starten →